Retatrutide is a triple hormone receptor agonist targeting GIP, GLP-1 and glucagon receptors. It is developed primarily for obesity and metabolic disease, with clinical trials showing substantial reductions in body weight and improvements in metabolic markers.

Benefits:

• Significant body-weight reduction
• Reduced appetite and food intake
• Improvements in blood glucose control
• Reduction in certain cardiometabolic risk factors
• Potential reduction in liver fat and improvement in metabolic health
• Obesity and overweight management outside clinical trials

• Improvements on Type 2 diabetes and related metabolic conditions

Potential Side Effects:

• Nausea
• Diarrhoea or constipation
• Reduced appetite

The COA is redacted to conceal our supplier name.